[Bleomycetin antitumor activity in relation to solid mouse tumors].
The antitumor activity of bleomycetin or bleomycin A5 was studied with respect to sarcoma 180, Garding-Passey melanoma, cervical carcinoma CC-5 and lymphosarcoma L10-1. Bleomycetin showed a high selective effect on the solid form of sarcoma 180. Its activity against Garding-Passeys melanoma and cervical carcinoma CC-5 was lower. Lymphosarcoma L10-1 was most resistant to bleomycetin. The intravenous route of bleomycin administration had no advantages over subcutaneous administration of the antibiotic.
D000818:Animals; D001761:Bleomycin / Q000627:therapeutic use* / Q000031:analogs & derivatives; D004353:Drug Evaluation, Preclinical; D005260:Female; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D051379:Mice; D008809:Mice, Inbred C3H; D008808:Mice, Inbred CBA; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D012510:Sarcoma 180 / Q000188:drug therapy; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy
D001761:Bleomycin; C025703:bleomycetin
Protivoopukholevaia aktivnost' bleomitsetina v otnoshenii plotnykh opukholeĭ mysheĭ.